+

WO2006005469A3 - Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur de glucagon (gcgr) - Google Patents

Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur de glucagon (gcgr) Download PDF

Info

Publication number
WO2006005469A3
WO2006005469A3 PCT/EP2005/007175 EP2005007175W WO2006005469A3 WO 2006005469 A3 WO2006005469 A3 WO 2006005469A3 EP 2005007175 W EP2005007175 W EP 2005007175W WO 2006005469 A3 WO2006005469 A3 WO 2006005469A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
gcgr
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2005/007175
Other languages
English (en)
Other versions
WO2006005469A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2006005469A2 publication Critical patent/WO2006005469A2/fr
Publication of WO2006005469A3 publication Critical patent/WO2006005469A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un GCGR humain, associé aux maladies cardiovasculaires, aux infections, aux maladies dermatologiques, aux maladies endocrinologiques, aux maladies métaboliques, au cancer, à l'inflammation, aux maladies gastroentérologiques, aux maladies hématologiques, aux maladies respiratoires, aux maladies des muscles squelettiques, aux maladies neurologiques ainsi qu'aux maladies urologiques.Par ailleurs, l'invention concerne des analyses d'identification de composés utilisés dans le traitement ou la prévention des maladies cardiovasculaires, des infections, des maladies dermatologiques, des maladies endocrinologiques, des maladies métaboliques, du cancer, de l'inflammation, des maladies gastroentérologiques, des maladies hématologiques, des maladies respiratoires, des maladies des muscles squelettiques, des maladies neurologiques ainsi que des maladies urologiques. L'invention concerne en outre des composés qui se lient à et/ou qui activent ou inhibent l'activité du GCGR humain, ainsi que des compositions pharmaceutiques qui contiennent ces composés.
PCT/EP2005/007175 2004-07-15 2005-07-02 Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur de glucagon (gcgr) WO2006005469A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04016639 2004-07-15
EP04016639.9 2004-07-15

Publications (2)

Publication Number Publication Date
WO2006005469A2 WO2006005469A2 (fr) 2006-01-19
WO2006005469A3 true WO2006005469A3 (fr) 2006-04-06

Family

ID=35285269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007175 WO2006005469A2 (fr) 2004-07-15 2005-07-02 Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur de glucagon (gcgr)

Country Status (1)

Country Link
WO (1) WO2006005469A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845802B2 (en) 2018-07-27 2023-12-19 Ngm Biopharmaceuticals, Inc. Combination therapy with a glucagon receptor (GCGR) antibody and an anti-CD3 antibody

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
PE20091674A1 (es) 2008-03-27 2009-11-04 Lilly Co Eli Antagonistas del receptor de glucagon
WO2009143014A1 (fr) * 2008-05-23 2009-11-26 Amylin Pharmaceuticals, Inc. Biodosages de l'agoniste du récepteur du glp-1
WO2017040986A1 (fr) 2015-09-04 2017-03-09 Remd Biotherapeutics, Inc. Méthodes de traitement de l'insuffisance cardiaque en utilisant des anticorps antagonistes du récepteur au glucagon
PE20191404A1 (es) 2017-01-27 2019-10-04 Ngm Biopharmaceuticals Inc Proteinas de union al receptor de glucagon y metodos para usarlas
EP3708577B1 (fr) 2017-11-06 2024-09-04 Shenzhen Turier Biotech Co., Ltd. Traitement de la cirrhose biliaire à base de peptide agoniste double cible de glp-1r/gcgr d'oxyntomoduline

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A. CRESPEL, F. DE BOISVILLIERS, L. GROS, AND A. KERVAN: "Effects of Glucagon and Glucagon like Peptide-1(7-36) Amide on C cells from Rat Thyroid and Medulary Thyroid carcinoma CA-77 Cell line", ENDOCRINOLOGY, vol. 137, no. 9, 1996, pages 3674 - 3680, XP002354960 *
DALLAS-YANG Q ET AL: "Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 501, no. 1-3, 6 October 2004 (2004-10-06), pages 225 - 234, XP004587613, ISSN: 0014-2999 *
DJURIC S W ET AL: "GLUCAGON RECEPTOR ANTAGONISTS FOR THE TREATMENT OF TYPE II DIABETES: CURRENT PROSPECTS", CURRENT OPINION IN INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, vol. 3, no. 11, November 2002 (2002-11-01), pages 1617 - 1623, XP001146198, ISSN: 0967-8298 *
EVA BRAND, LISE BANKIR, PIERRE-FRANÇOIS PLOUIN, FLORENT SOUBRIER: "Glucagon Receptor Gene Mutation (Gly40Ser) in Human Essential Hypertension The Pegase study", HYPERTENSION, July 1999 (1999-07-01), XP002354964 *
JEAN-CLAUDE MARIE,CLAUDINE BOISSARD, GUNNAR SKOGLUND, GABRIEL ROSSELIN, BERNADETTE BREANT: "Glucanon Acts Through Its Own Receptors in the Presence of Functional Glucagon-like Peptide-1 Receptors on Hamster Insulinoma", ENDOCRINOLOGY, vol. 137, no. 10, 1996, pages 4108 - 4114, XP002354962 *
MARGARET A. CASCIERI ET AL: "Characterization of a novel, non-Peptidyl Anatgonist of the human Glucanon Receptor", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 13, 26 March 1999 (1999-03-26), pages 8694 - 8697, XP002218972 *
MICHAEL SVOBODA, LAURENCE PORTOIS AND WILLY J. MALAISSE, MOLECULAR GENETICS AND METABOLISM, vol. 68, 1999, pages 258 - 267, XP002354963 *
SCHMIDT-KASTNER R ET AL: "GENES NEWLY CONNECTED TO BRAIN ISCHEMIA BY DNA MICROARRAY ANALYSIS AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN RAT.", SOCIETY FOR NEUROSCIENCE - ABSTRACT VIEWER AND ITINERARY PLANNER - PROGRAM NO. 694.6, 2002, Washington DC, XP002354961, Retrieved from the Internet <URL:http://sfn.scholarone.com/itin2002/main.html?new_page_id=126&abstract_id=4147> [retrieved on 20051104] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845802B2 (en) 2018-07-27 2023-12-19 Ngm Biopharmaceuticals, Inc. Combination therapy with a glucagon receptor (GCGR) antibody and an anti-CD3 antibody

Also Published As

Publication number Publication date
WO2006005469A2 (fr) 2006-01-19

Similar Documents

Publication Publication Date Title
WO2006027147A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d&#39;adrenomedulline (amdr)
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2006005469A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur de glucagon (gcgr)
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2006010517A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la proteine d&#39;activation des fibroblastes (fap)
WO2005100990A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au purinocepteur 2 de type y (p2y2)
WO2005103684A3 (fr) Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c
WO2005031345A3 (fr) Diagnostic et therapeutique de maladies associees au recepteur couple a la proteine g adipor2 (adipor2)
WO2005076007A3 (fr) Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12)
WO2006021343A3 (fr) Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a)
WO2005119263A3 (fr) Diagnostic et traitement des maladies associees au recepteur couple aux proteines g 92 (gpr92)
WO2005101001A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees au recepteur couple a la proteine g, element c, groupe 5, famille c (gprc5c)
WO2005073729A3 (fr) Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11)
WO2005075983A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3)
WO2005074969A3 (fr) Diagnostics et traitements de maladies associees au recepteur nucleaire humain nr4a1 (nr4a1)
WO2005113786A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1)
WO2006005461A3 (fr) Diagnostic et traitement des maladies associees au recepteur 27 couple aux proteines g (rcpg 27)
WO2006008003A3 (fr) Agents diagnostiques et therapeutiques pour pathologies associees au recepteur 1 de peptide intestinal vasoactif (vpac1)
WO2006005470A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees au recepteur couple a la proteine g lie au mas (mrge)
WO2005101011A3 (fr) Agents diagnostiques therapeutiques pour des maladies associees a lxr-alpha (lxra)
WO2005113788A3 (fr) Diagnostics et therapeutiques pour des maladies associees a la kinase 6 associee au recepteur couple a une proteine g (grk6)
WO2005106486A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3)
WO2005114210A8 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees a la kinase 3 specifique du recepteur couple a une proteine g (grk3)
WO2006010515A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la 5-hydroxytryptamine 2a (5ht2a)
WO2005075990A3 (fr) Diagnostics et therapeutiques pour maladies associees au recepteur nucleaire humain nr4a2 (nr4a2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载